Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in New York

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Literacy to Targeted Exposure Concerns

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge, empowering individuals to make informed decisions about their well-being. This legacy of accessible health information has built a foundation of trust and awareness, enabling the public to engage with complex medical topics as they evolve. In recent years, however, the focus has shifted from general health maintenance to specific, high-stakes exposures that arise from widely adopted therapeutic interventions. One such area of concern involves the use of glucagon-like peptide-1 receptor agonists, originally developed for metabolic management, and their potential association with delayed gastric emptying. This transition from a general health context to a more targeted occupational exposure concern reflects a growing need to understand how routine clinical treatments may intersect with legal and regulatory frameworks. As patients and healthcare providers navigate these emerging risks, the question of timely legal recourse becomes paramount. In New York, for instance, individuals who have used medications like Ozempic and subsequently developed gastroparesis must consider the statute of limitations for filing claims. This pivot from general health literacy to specific exposure-related liability underscores the importance of adapting public health narratives to address the practical consequences of pharmaceutical use.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or more invasive interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology involves mimicking the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This mechanism of action is central to its therapeutic efficacy but also underlies its gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Evidence and Clinical Data

The mechanistic pathway linking Ozempic to gastroparesis is rooted in its effect on gastric motility. GLP-1 receptor agonists delay gastric emptying, which can exacerbate or unmask underlying gastroparesis. While the prescribing information for Ozempic does not explicitly list gastroparesis as a warning, it does document gastrointestinal adverse reactions including nausea, vomiting, diarrhea, abdominal pain, and constipation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specifically, in placebo-controlled trials, nausea occurred in 15.8% of patients on Ozempic 0.5 mg and 20.3% on Ozempic 1 mg, compared to 6.1% on placebo; vomiting occurred in 5.0% and 9.2% respectively, versus 2.3% on placebo; and abdominal pain occurred in 7.3% and 5.7% respectively, versus 4.6% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, raising questions about the adequacy of warnings regarding the potential for this condition. From a risk perspective, patients who develop gastroparesis after using Ozempic may consider legal action if they believe the manufacturer failed to adequately warn about this risk. The adequacy of warnings is a key factor in product liability claims. The prescribing information for Ozempic includes a section on hypersensitivity reactions, such as anaphylaxis and angioedema, but does not specifically address gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission could be argued as insufficient to alert patients and healthcare providers to the potential for delayed gastric emptying severe enough to cause gastroparesis.

Legal Considerations and Statute of Limitations in New York

Settlement-related considerations for affected patients include the need to document the timeline between exposure to Ozempic and the onset of gastroparesis symptoms. The majority of gastrointestinal adverse reactions in clinical trials occurred during dose escalation, suggesting that early exposure is a critical period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, symptoms may persist or worsen over time, and the condition can become chronic. Patients should gather medical records showing the date of first Ozempic use, dose changes, and the diagnosis of gastroparesis, along with any diagnostic tests such as gastric emptying studies. In New York, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For product liability claims, the statute may vary depending on the theory of liability (e.g., negligence, strict liability, failure to warn). It is crucial for affected patients to consult with a New York attorney experienced in pharmaceutical litigation to determine the applicable deadline for their specific case. Delays in filing can result in the loss of the right to seek compensation. The timeline between exposure and documented harm is central to establishing causation. Patients who used Ozempic and subsequently developed gastroparesis should have their medical records reviewed to confirm that the onset of symptoms aligns with the known gastrointestinal effects of the drug. Given that gastrointestinal adverse reactions are common and often dose-related, a temporal association can strengthen a claim. However, other causes of gastroparesis, such as diabetes itself (which is the underlying condition being treated), must be ruled out. In summary, the link between Ozempic and gastroparesis is biologically plausible given the drug's mechanism of delaying gastric emptying. Clinical trial data show a high incidence of gastrointestinal symptoms, but the prescribing information does not explicitly warn about gastroparesis. Patients in New York who have developed this condition after using Ozempic should be aware of the three-year statute of limitations and seek legal advice promptly. Documentation of the exposure timeline and medical diagnosis is essential for any potential settlement or litigation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For product liability claims, the statute may vary depending on the theory of liability. It is crucial to consult with a New York attorney experienced in pharmaceutical litigation to determine the applicable deadline for your specific case.

What evidence is needed to support an Ozempic gastroparesis claim?

Patients should gather medical records showing the date of first Ozempic use, dose changes, and the diagnosis of gastroparesis, along with any diagnostic tests such as gastric emptying studies. Documentation of the timeline between exposure and symptom onset is essential to establish causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.